山东医药2016，Vol.56Issue(17)：22-25,4.DOI:10.3969/j.issn.1002-266X.2016.17.007
EGFR 19-del 和 L858R 突变型 NSCLC患者预后比较
Comparison of prognosis between EGFR 19-del and L858R mutations in patients with non-small-cell lung cancer
摘要
Abstract
Objective To compare the prognosis between the epidermal growth factor receptor ( EGFR) exon 19 (19-del) mutation and exon 21 L858R (L858R) mutation in patients with non-small-cell lung cancer (NSCLC).Methods Totally 257 cases of NSCLC patients were selected.The fresh tissues or paraffin embedding tissues were obtained, and the EGFR genotypes were detected by ARMS-PCR.Meanwhile, we collected the clinical data, and the patients were followed up by using the death as the end.Patients without follow-up or the patients who did not have the outcome until the end of the follow-up were all brought into the censored data.All data were analyzed by SPSS17.0 software.Results There were 134 cases with 19-del mutation and 123 cases with L858R mutation in 257 patients.No significant difference was found in the distribution of clinical characteristic between the two groups (P>0.05).The survival analysis showed that the median survival time of 19-del mutation was 798 d and that of L858R mutation was 710 d, and the overall survival time had no sta-tistical difference in these two groups (P>0.05).Subsequently, the result from the stratified analysis revealed that the prognosis in patients with 19-del mutation was better than that of L858R mutation in Han nationality (P=0.047), and no significant difference was found in Zhuang nationality (P>0.05).Meanwhile, the overall survival time showed no statisti-cally difference in age, gender, TNM stages and clinical stages between 19-del and L858R mutations (all P>0.05). Conclusion The overall survival time is the same between NSCLC patients with 19-del mutation and with L858R muta-tion, but the prognosis of patients with 19-del mutation is better than that of L858R mutation in Han nationality.关键词
肺肿瘤/表皮生长因子受体突变/19外显子突变/21外显子L858R突变/预后分析Key words
lung carcinoma/epidermal growth factor receptor mutation/exon 19 mutation/exon 21 L858R mutation/prognostic analysis分类
医药卫生引用本文复制引用
韦文娥,利基林,宁淑芳,刘海洲,蔡政民,张力图..EGFR 19-del 和 L858R 突变型 NSCLC患者预后比较[J].山东医药,2016,56(17):22-25,4.基金项目
广西科学研究与技术开发计划基金资助项目（桂科攻1298003-2-8；桂科攻1355005-3-10）。 （）
